48 results about "Mapk signaling pathway" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides a medicine for treating chronic obstructive pulmonary disease. The medicine comprises kaempferol or pharmaceutically acceptable salt thereof as an active ingredient. The invention aims to provide the application of kaempferol in preparation of the medicine for treating the chronic obstructive pulmonary disease, and the chronic obstructive pulmonary disease is treated by adjusting an AMPK signal channel, a Hippo signal channel, an MAPK signal channel and a PI3K-AKT signal channel.

The invention belongs to the technical field of biological medicines, and particularly discloses application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. According to the application of the (E)-BCI hydrochloride in preparation of the medicine for treating sepsis, by inhibiting the activity of bispecific phosphatase 6, a mitogen activated protein kinase signal channel is regulated and controlled, and the expression level of inflammatory factors IL-1beta and TNF-alpha is reduced. The invention discloses application of (E)-BCI hydrochloride in preparation of drugs for treating sepsis, BCI enters from a new target for regulating inflammation and immune balance through a targeted DUSP6 / MAPK signal channel, a non-antibiotic-dependent drug is provided for treatment of sepsis, and the (E)-BCI hydrochloride is especially suitable for systemic inflammatory response syndromes caused by infection, operations, wounds and other inducements, and has a wide application prospect. Wide clinical application prospects are realized.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of FKBP10 in diagnosis and treatment of atherosclerosis. Specifically, the invention demonstrates that FKBP10 promotes the unique effect of EndMT in vascular pathology, which is associated with increasing the phenotypes of atherosclerosis and unstable plaques. The invention proves that FKBP10 promotes membrane localization of PARP1, activates PI3K / AKT and MAPK signal pathways, induces EndMT and promotes atherosclerosis and poor prognosis of patients. Meanwhile, EndMT is inhibited by screening a small molecule drug TAK733, and a new scheme is provided for clinical treatment of atherosclerosis, so that the application has good potential practical application value.

The invention provides an application of protocatechuic acid in an anti-inflammatory active pharmaceutical composition in dairy cow mammary epithelial cells, belongs to the technical field of bioengineering, and aims to obtain high-purity protocatechuic acid (greater than or equal to 95%) by optimizing a preparation process through the application of protocatechuic acid in inhibition of inflammatory response of dairy cow mammary epithelial cells. Under the concentration of 1-100 mu M, the level of inflammatory factors such as TNF-alpha, IL-6 and the like is remarkably reduced (the inhibition rate is larger than or equal to 60%), the mechanism is that NF-kB and MAPK signal channels are inhibited, cytotoxicity is avoided, and a milk region perfusion agent or a feed additive can be prepared to be used for preventing and treating dairy cow mastitis.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The invention relates to an application of a bioactive peptide YPFPGPIH derived from bovine casein in the aspect of anti-inflammation or immunoregulation. The peptide can be combined with TLR2 and TLR4 to inhibit the activation of NF-kappa B and MAPK signal channels, so that the levels of inflammatory factors such as IL-1beta, TNF-alpha and NO are remarkably reduced, the expression of IL-10 is up-regulated, and inflammation balance regulation is realized; the body inflammatory response is improved, and the immune organ injury is recovered. The peptide can be used for preparing anti-inflammatory drugs, immunomodulatory functional foods and nutritional supplements, and has good safety and application prospects.

The present invention relates to the technical field of drug synthesis. Specifically, a six-membered lactam compound and a use thereof are provided, the compound having a structure represented by formula I, or stereoisomers, tautomers, racemates thereof, or pharmaceutically acceptable salts, esters, solvates, polymorphs, nitrogen oxides, isotope labels, metabolites, hydrates thereof, the structure represented by formula I being formula (I). The compound and a composition can be used to prepare an MEK or Ras-MAPK signaling pathway inhibitor, which has better activity, can fully inhibit the MEK or Ras-MAPK signaling pathway, and provides a new way to treat diseases related to the MEK or Ras-MAPK signaling pathway.

This invention discloses a coumarin compound and its uses, belonging to the field of chemical and pharmaceutical technology. This invention provides coumarin compounds represented by Formula I, particularly some specific coumarin compounds. These compounds and their compositions can inhibit the MEK or Ras-MAPK signaling pathway, providing a new approach for treating diseases related to the MEK or Ras-MAPK signaling pathway.

The present invention relates to the technical field of chemicals and pharmaceuticals. Disclosed are a coumarin compound and a use thereof. The present invention provides a coumarin compound represented by formula I, and some specific coumarin compounds. The compound and composition can effectively inhibit MEK or Ras-MAPK signaling pathways, can be used for preparing MEK or Ras-MAPK signaling pathway inhibitors, and provide a new way for treating MEK or Ras-MAPK signaling pathway-related diseases.

This invention relates to the field of plant disease biological control technology, and particularly to a Fusarium oxysporum cell wall extract, its preparation method, and its application. The extract is derived from the polysaccharide fraction of the cell wall of Fusarium oxysporum spores or hyphae, and contains at least one pathogen-associated molecular pattern (PAMP) component. This component is a non-protein, thermally stable, species-nonspecific elicitor capable of forming an aqueous dispersion system. The extract of this invention can be recognized by plant PRRs and activate PTI immunity. Rehmannia glutinosa tubers treated with the extract showed a significantly increased germination rate after inoculation with Fusarium oxysporum. It also induces superoxide anion production, upregulates the activities of superoxide dismutase, peroxidase, and catalase, and enriches differentially expressed genes in the MAPK signaling pathway, jasmonic acid metabolism pathway, and phenylpropane biosynthesis pathway. Furthermore, the extract can directly inhibit Fusarium oxysporum colony expansion, conidia production, and mycelial growth. Extracts derived from spores or hyphae show no significant difference in inducing disease resistance, and the raw materials are flexible and easy to industrialize. This extract is derived from the cell wall of the pathogen itself, making it environmentally friendly and free from the risk of chemical pesticide residues. It is suitable for the green control of root rot disease in Rehmannia glutinosa.

The application discloses a caviar polypeptide composition with enhanced immune function, a preparation method, application and preparation, belongs to the technical field of bioactive polypeptides, and comprises at least one polypeptide with an amino acid sequence of RWFPGKPLFWRA, FWKPLRGALFPW or KWRFPGALPWFA and a molecular weight of 1400-1550 Da. The preparation method comprises caviar protein extraction, complex enzymolysis, ultrafiltration separation, chromatography purification and solid-phase synthesis. Animal experiments prove that the polypeptide can significantly enhance cell immunity, humoral immunity, monocyte-macrophage function and NK cell activity, the mechanism is related to TLR2 / TLR4 receptor activation and NF-κB / MAPK signal pathways, the safety is good, and the polypeptide is suitable for development into an immune-enhancing health food or medicine.

This invention belongs to the field of active ingredient extraction and purification technology, specifically a neutral polysaccharide ORP-0 from *Agaricus bisporus* and its applications. The preparation method of this invention includes the following steps: (1) pretreatment; (2) polysaccharide extraction; (3) impurity removal; and (4) separation and purification. This invention obtains a single neutral polysaccharide ORP-0 through defatting pretreatment, ultrasonic-assisted extraction, multiple impurity removal processes, and separation and purification using a DEAE-52 cellulose chromatography column. The method of this invention is simple to operate, has mild reaction conditions, and a complete impurity removal process. The obtained neutral polysaccharide has high purity, with a total sugar content of 92.09%. Furthermore, the obtained neutral polysaccharide ORP-0 enhances the activity of RAW 264.7 macrophages, increases the release of immune factors, enhances the expression of phosphorylated proteins in the MAPK signaling pathway, and activates the body's immune response.

The present application relates to the technical field of genetic engineering, and particularly relates to long-chain RNA Lnc_012227 for inhibiting ovary transmission of Salmonella enteritidis and application of the long-chain RNA Lnc_012227 in preventing and controlling Salmonella enteritidis infection.A long-chain RNA Lnc_012227 for inhibiting ovary transmission of Salmonella enteritidis.The Lnc_012227 provided by the present application can indirectly regulate expression of MAP3K8, activate NF-kappa B and MAPK signaling pathways, and enhance inflammatory response of a host, so as to control S.Enteritidis infection.This finding not only provides new molecular level understanding for understanding infection mechanism of Salmonella in duck bodies, but also provides a potential target for developing a new treatment strategy, and is helpful for reducing ovary infection of Salmonella and duck egg pollution caused by Salmonella.

The invention relates to the technical field of biological medicine, in particular to application of TOMM40 in preparation of a medicine for treating breast cancer. The invention finds that TOMM40 overexpression promotes the increase of the content of DDR1 in lipid rafts instead of early-stage endosomes; a co-immunoprecipitation experiment shows that TOMM40 and PHB2 interact with DDR1 and SRC, and DDR1 and SRC also interact with each other; the combination of TOMM40 and PHB2 can promote phosphorylation activation of DDR1, the activated DDR1 further promotes activation of SRC interacting with the activated DDR1, activation of a downstream MAPK signal channel is caused, and meanwhile, the activated DDR1 can directly activate an AKT / mTOR channel; furthermore, the invention finds that the killing ability of tumor cells can be obviously enhanced by further utilizing Flurizoline and DDR1-IN-1 to treat the breast cancer cells, and the method is expected to become a new strategy for breast cancer treatment.

The application discloses a benzofuran derivative, which has a structure shown in formula (I), and discloses a pharmaceutical composition and application in preparation of anti-inflammatory drugs. The application can effectively inhibit LPS-induced inflammation in vivo and in vitro, and can play an anti-inflammatory role by inhibiting the release of inflammatory factors TNF-alpha and IL-6 through inhibition of NF-kappa B and MAPK signal pathways.

The invention belongs to the technical field of biological medicine and pharmacology, and particularly relates to EGCG-5-HT binary oxidation self-agglutination nanoparticles as well as a preparation method and application of the EGCG-5-HT binary oxidation self-agglutination nanoparticles. The EGCG (epigallocatechin gallate)-5-HT binary oxidation auto-agglutination nanoparticles disclosed by the invention are obtained by carrying out oxidation auto-agglutination on EGCG and 5-HT in an alkaline environment. The total concentration of the EGCG and the 5-HT in the reaction liquid is 1.0 to 3.0 mg / mL. The nanoparticles provided by the invention have an anti-oxidation effect, and can inhibit pyroptosis and regulate and control a cell cycle; an NF-kappa B signal channel is inhibited, and the anti-inflammatory effect is achieved; an MAPK signal channel is activated, and cell apoptosis is inhibited; a PI3K-Akt signal channel is activated, and cell proliferation and mucous membrane repair are promoted. When the compound is applied to preparation of IBD medicines, multi-mechanism synergistic treatment of anti-inflammatory, anti-oxidation and mucous membrane repair of IBD is realized; the invention also provides a preparation method of the nanoparticle, and the preparation method is mild in condition and simple.

The invention provides a water-based surfactant preparation for relieving atopic dermatitis and application, and belongs to the field of external preparation development. The active ingredient of the aqueous surfactant preparation is an anionic surfactant for inhibiting an STAT3 signal. NF-kappa B and MAPK signal channels are indirectly inhibited by inhibiting STAT3 activation, and expression of inflammatory factors is remarkably reduced. Compared with a traditional surfactant SLS, the water-based surfactant preparation does not affect cell activity, shows good anti-inflammatory activity in vivo and in vitro, has the advantages of relieving atopic dermatitis skin lesion, reducing serum IgE level, relieving mast cell infiltration and the like, and provides a safer cleaning or external anti-inflammatory choice for AD patients. Therefore, the traditional surfactant is utilized to relieve the inflammation of atopic dermatitis, and meanwhile, the problem that the traditional surfactant irritates skin and aggravates inflammatory response is avoided.

The invention belongs to the technical field of medicines, and particularly relates to application of traditional Chinese medicine active ingredients in antianaphylaxis, in particular to application of rare ginsenoside Rh1 in preparation of medicines for preventing or treating anaphylaxis. According to the invention, the action mechanism of Rh1 in resisting anaphylaxis is systematically clarified by integrating network pharmacology, molecular docking, molecular dynamics simulation and transcriptomics technologies for the first time. The Rh1 acts on four key host targets, namely ALB, CASP3, NFKB1 and STAT3 at the same time, regulates and controls an MAPK signal channel, a Th17cell diffusion channel and a PI3K-Akt signal channel, and synergistically exerts the dual effects of inhibiting allergens from invading host cells and relieving cytokine storm. The Rh1 and the four key targets all have high affinity binding. The invention provides a brand new theoretical basis and a clear mechanism support for developing Rh1-based broad-spectrum, high-efficiency and low-toxicity anti-anaphylaxis drugs.

The invention relates to the technical field of biology, in particular to a TLR2 / TLR4 activating peptide-based CAR-T cell as well as a preparation method and application thereof. Through lentiviral vector transduction, the T cell co-expresses the following components: a) a mesothelin-targeted chimeric antigen receptor CAR; and b) an exogenous oligopeptide EEIYEEFA (SEQ ID NO: 1), which is used for up-regulating downstream NF-kappa B and MAPK signal channels by activating TLR2 / TLR4 so as to further improve the secretion levels of IFN-gamma, IL-2 and GranzymeB (P is less than 0.01). The invention has the advantages that: a T cell TLR2 / TLR4 signal channel is activated by secreting PEP, and M2 type macrophages are polarized into M1 type macrophages, so that the solid tumor treatment effect is obviously enhanced. The cell inhibits tumor growth by 70% in a lung cancer tumor-bearing model, prolongs the lifetime of mice to 45 days, and has important clinical application value.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The present application relates to a kind of drug based on PARM1 regulation treatment calcified aortic valve disease and its application.The present application first finds that PARM1 is significantly increased in the aortic valve of calcified aortic valve disease (CAVD) patient, and plays a key role in the osteogenic differentiation process of valve interstitial cells (VICs), and the expression level of PARM1 is knocked down can inhibit the osteogenic differentiation of VICs and extracellular calcium salt deposition, reduce aortic valve calcification, and its mechanism of action involves MAPK signal pathway.The present application provides a new target and treatment idea for the treatment of CAVD, and can be applied to related drug research and development and treatment method development.

The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same. Activation of the p42 / 44 MAPK signaling pathway, including mitogen-activated protein kinase / extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK, has been implicated in the etiology and progression of various cancers. The MEK-ERK pathway is often activated by mutations in the upstream factors BRAF or Ras, or by signals from structurally activated cell surface receptors. Inhibition of MEK may be a promising strategy for controlling the growth of tumors, such as tumors associated with MEK pathway signaling.

The present invention provides a use of a ugonin compound for the treatment of joint-related diseases by enhancing chondrogenesis. More specifically, the chondrogenesis is mediated by the ugonin compound’s ability to promote the increase of aggrecan and type II collagen, which is achieved through the inhibition of miR-3074-5p and the activation of the MAPK signaling pathway.

The invention discloses a low-salt dry-cured mackerel polypeptide as well as a preparation method and application thereof in anti-inflammation, and belongs to the technical field of fermented food. According to the method, lactobacillus plantarum is inoculated, the addition amount of table salt in the pickling process is reduced, the low-salt dry-pickled mackerel is prepared, and 10 gamma-glutamic acid containing peptides are extracted through separation and purification. Experimental results show that the 10 gamma-glutamic acid containing peptides all have different degrees of anti-inflammatory potentials. Wherein the gamma-glutamic acid-containing peptide with the amino acid sequence shown as SEQ ID NO.2 can significantly down-regulate the phosphorylation level of NF-kB, JNK, P38MAPK and ERK in RAW264.7 mouse inflammation model cells, so that an MAPK signal channel is inhibited, massive secretion of an inflammatory mediator NO and pro-inflammatory cytokines IL-6 and TNF-alpha is inhibited, and the gamma-glutamic acid-containing peptide has outstanding anti-inflammatory activity and can be developed into anti-inflammatory drugs.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The invention discloses a PKN3 kinase inhibitor, a pharmaceutical composition and a preparation method and application of the PKN3 kinase inhibitor. The PKN3 kinase inhibitor RI further prevents RAF family protein and CDC37-HSP90 from forming a stable compound by inhibiting activation of CDC37, and reduces the stability and activation level of RAF protein, so that down-regulation of an MAPK signal channel is realized, and proliferation and survival of tumor cells are inhibited; meanwhile, the PKN3 kinase inhibitor RI and the MEK inhibitor are combined for use, so that the treatment effect is excellent, and the drug resistance problem caused by single-channel inhibition can be remarkably solved. The PKN3 kinase inhibitor RI is a novel molecular targeting drug which can target an RAF regulation mechanism and is suitable for BRAF wild type melanoma, and fills the technical blank that the BRAF wild type melanoma is lack of effective treatment drugs and means for a long time.

The application of TAB2 protein in rabies treatment target spot belongs to the field of biological medicine technology. In order to study the influence of host protein on RABV replication, further study the pathogenic molecular mechanism of RABV, and find new rabies treatment target and drug, the application uses fluorescence quantification, Western Blotting and other methods to study the influence of host protein TAB2 on RABV replication, and finds that TAB2 gene transient knockdown or stable knockdown can inhibit the replication of rabies virus, and further finds that TAB2 protein can be used as a new target for rabies treatment. In addition, the application also finds the structure domain of TAB2 and RABV M interaction and the TAB2 protein promotes RABV replication by activating TAK1-p38 / MAPK signal pathway, and the p38 inhibitor Gossypetin and the TAK1 inhibitor Takinib can be used as potential drugs for treating RABV infection.

The application discloses application of a large-mouth black bass stomach polypeptide in preparation of an antioxidant and / or immunoregulation product, relates to the field of bioactive peptides, and is characterized in that the large-mouth black bass stomach polypeptide is a polypeptide product obtained by alkaline protease enzymolysis of large-mouth black bass stomach, and components with molecular weights less than 3000 Da account for more than 98% of the total peptide amount. The polypeptide has significant DPPH free radical, hydroxyl free radical and ABTS cationic free radical scavenging capacity and reducing capacity, can promote macrophage proliferation, enhance phagocytosis, promote nitric oxide secretion, up-regulate immune-related cytokine expression, and play an immunoregulation role through activation of P38 and P44 MAPK signal pathways. The application realizes high-value utilization of large-mouth black bass processing by-products, has high product safety, and has a wide application prospect.

The invention discloses application of a D-dopa pigment isomerase inhibitor in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The invention defines that D-DT is an independent and key driving factor for rheumatoid arthritis, especially for the pathological behavior of fibroblast-like synovial cells. The specific molecular mechanism that D-DT plays a role in FLS through an MAPK signal path-COX-2 / PGE2 signal axis is systematically clarified for the first time, and a complete'target spot-pathway-function 'chain is formed. In-vitro and in-vivo experiments prove that selective inhibition of D-DT can effectively relieve disease symptoms and pathological progression, and solid principle verification is provided for development of a new therapy.